Mahkam Zanganeh
Mahkam Zanganeh's purchase track record
How the stock did after each of Mahkam Zanganeh's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/12/2026 | SMMT | $49.99M | +25.3% | pending | — |
| 6/4/2026 | SMMT | $1.46M | +15.4% | pending | — |
| 10/21/2025 | SMMT | $500K | -14.3% | +40.8% | +4.9% |
| 9/10/2025 | SMMT | $5.98M | +1.9% | -8.7% | +3.7% |
| 3/26/2024 | SMMT | $411K | +114.2% | +541.7% | +10.2% |
| 12/12/2023 | SMMT | $10K | +95.9% | +242.7% | +15.8% |
| 3/8/2023 | SMMT | $24.70M | +23.7% | +2.6% | +11.9% |
| 8/16/2022 | SMMT | $5.63M | +7.9% | +105.9% | -3.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Pulse Biosciences Partners with Clayman Thyroid Center. Pulse Biosciences announced a commercial and clinical partnership with the Clayman Thyroid Center in Tampa, Florida. Additionally, Oppenheimer raised its price target to $60 and maintained an Outperform rating, citing the importance of the 2027 trial readout for the company's new ablation modality. The stock recently saw a 12.3% rise following the completion of full enrollment for the NANOPULSE-AF trial.
Transaction History
| SMMT | ▲ Buy | Open Market | 3,810,000 | $50.0M | 6/12/2026 | View on chart |
| SMMT | ▲ Buy | Open Market | 100,000 | $1.5M | 6/4/2026 | View on chart |
| SMMT | ▲ Buy | Open Market | 26,680 | $500K | 10/21/2025 | View on chart |
| SMMT | ▲ Buy | Grant | 13,980,789 | $262.0M | 10/21/2025 | View on chart |
| SMMT | ▲ Buy | Grant | 266,808 | $5.0M | 10/21/2025 | View on chart |
| SMMT | ▲ Buy | Open Market | 5,000 | $90K | 9/11/2025 | View on chart |
| SMMT | ▲ Buy | Open Market | 333,394 | $5.9M | 9/10/2025 | View on chart |
| SMMT | ▲ Buy | Option Exercise | 74,545 | $197K | 5/30/2025 | View on chart |
| SMMT | ▼ Sell | Other | 3,985,055 | $6.3M | 4/8/2025 | View on chart |
| PLSE | ▼ Sell | Other | 30,121 | $331K | 2/3/2025 | View on chart |
| PLSE | ▼ Sell | Other | 30,121 | $331K | 1/24/2025 | View on chart |
| SMMT | ▼ Sell | Other | 315,681 | $499K | 10/3/2024 | View on chart |
| SMMT | ▲ Buy | Grant | 44,052 | $1000K | 9/11/2024 | View on chart |
| PLSE | ▼ Sell | Other | 60,242 | — | 7/3/2024 | View on chart |
| SMMT | ▲ Buy | Open Market | 20,000 | $74K | 3/27/2024 | View on chart |
| SMMT | ▲ Buy | Open Market | 34,321 | $128K | 3/27/2024 | View on chart |
| SMMT | ▲ Buy | Open Market | 26,000 | $97K | 3/27/2024 | View on chart |
| SMMT | ▲ Buy | Open Market | 30,000 | $113K | 3/26/2024 | View on chart |
| SMMT | ▲ Buy | Open Market | 5,000 | $10K | 12/12/2023 | View on chart |
| SMMT | ▼ Sell | Other | 315,681 | $499K | 12/11/2023 | View on chart |
| SMMT | ▼ Sell | Other | 489,814 | $705K | 12/11/2023 | View on chart |
| PLSE | ▲ Buy | Option Exercise | 20,000 | $43K | 11/13/2023 | View on chart |
| PLSE | ▲ Buy | Option Exercise | 56,075 | $120K | 11/13/2023 | View on chart |
| PLSE | ▼ Sell | Other | 86,668 | $178K | 6/9/2023 | View on chart |
| SMMT | ▲ Buy | Open Market | 15,973,743 | $16.8M | 3/8/2023 | View on chart |
| SMMT | ▲ Buy | Open Market | 804,672 | $845K | 3/8/2023 | View on chart |
| SMMT | ▲ Buy | Open Market | 6,748,629 | $7.1M | 3/8/2023 | View on chart |
| SMMT | ▼ Sell | Other | 373,857 | — | 12/6/2022 | View on chart |
| SMMT | ▲ Buy | Open Market | 1,030,925 | $1000K | 8/16/2022 | View on chart |
| SMMT | ▲ Buy | Open Market | 184,430 | $179K | 8/16/2022 | View on chart |
| SMMT | ▲ Buy | Open Market | 4,593,777 | $4.5M | 8/16/2022 | View on chart |
| PLSE | ▼ Sell | Other | 86,668 | — | 6/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Summit Therapeutics Partners With AstraZeneca and Daiichi Sankyo
Summit Therapeutics announced a new collaboration with AstraZeneca and Daiichi Sankyo to test a cancer therapy combination. This partnership involves an ADC-bispecific approach and was described by the CEO as an important expansion of the company’s work. The stock rose 7.3% following the news, reflecting investor interest in this strategic alliance.
Summit Therapeutics Partners With AstraZeneca and Daiichi Sankyo. Summit Therapeutics announced a new collaboration with AstraZeneca and Daiichi Sankyo to test a cancer therapy combination. This partnership involves an ADC-bispecific approach and was described by the CEO as an important expansion of the company’s work. The stock rose 7.3% following the news, reflecting investor interest in this strategic alliance.